Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches

被引：269

作者：

Thoenen, H

Sendtner, M

机构：

[1] Max Planck Inst Neurobiol, D-82152 Martinsried, Germany

[2] Inst Clin Neurobiol, D-97080 Wurzburg, Germany

来源：

NATURE NEUROSCIENCE | 2002年 / 5卷 / Suppl 11期

关键词：

D O I：

10.1038/nn938

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Despite high enthusiasm, early attempts to develop clinical treatments based on animal research with neurotrophins were not successful. Here we survey clinical trials with neurotrophins, compared with neurotrophic factors of other gene families, and delineate the most likely reasons for their failure. We then suggest improved methods for regulated local supply of NTs to specific populations of neurons and discuss future therapeutic procedures evolving from the more detailed knowledge of the signal transduction pathways activated by neurotrophins via their receptors.

引用

收藏

页码：1046 / 1050

页数：5

相关论文

共 55 条

[1] Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients [J].

Aebischer, P ;

Schluep, M ;

Deglon, N ;

Joseph, JM ;

Hirt, L ;

Heyd, B ;

Goddard, M ;

Hammang, JP ;

Zurn, AD ;

Kato, AC ;

Regli, F ;

Baetge, EE .

NATURE MEDICINE, 1996, 2 (06) :696-699

[2] Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy - A randomized controled trial [J].

Apfel, SC ;

Schwartz, S ;

Adornato, BT ;

Freeman, R ;

Biton, V ;

Rendell, M ;

Vinik, A ;

Giuliani, M ;

Stevens, JC ;

Barbano, R ;

Dyck, PJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (17) :2215-2221

[3] Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy [J].

Apfel, SC ;

Kessler, JA ;

Adornato, BT ;

Litchy, WJ ;

Sanders, C ;

Rask, CA .

NEUROLOGY, 1998, 51 (03) :695-702

[4] Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF [J].

Bachoud-Lévi, AC ;

Déglon, N ;

Nguyen, JP ;

Bloch, J ;

Bourdet, C ;

Winkel, L ;

Rémy, P ;

Goddard, M ;

Lefaucheur, JP ;

Brugières, P ;

Baudic, S ;

Cesaro, P ;

Peschanski, M ;

Aebischer, P .

HUMAN GENE THERAPY, 2000, 11 (12) :1723-1729

[5]

Baekelandt V, 2000, CURR OPIN MOL THER, V2, P540

[6]

BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B

[7] Critical periods during sensory development [J].

Berardi, N ;

Pizzorusso, T ;

Maffei, L .

CURRENT OPINION IN NEUROBIOLOGY, 2000, 10 (01) :138-145

[8] Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system [J].

Bibel, M ;

Barde, YA .

GENES & DEVELOPMENT, 2000, 14 (23) :2919-2937

[9] BDNF and epilepsy: too much of a good thing? [J].

Binder, DK ;

Croll, SD ;

Gall, CM ;

Scharfman, HE .

TRENDS IN NEUROSCIENCES, 2001, 24 (01) :47-53

[10] A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis [J].

Borasio, GD ;

Robberecht, W ;

Leigh, PN ;

Emile, J ;

Guiloff, RJ ;

Jerusalem, F ;

Silani, V ;

Vos, PE ;

Wokke, JHJ ;

Dobbins, T .

NEUROLOGY, 1998, 51 (02) :583-586

← 1 2 3 4 5 6 →